Mr. Hayim Raclaw reports

ALZAI HEALTH CORP. SIGNS STRATEGIC U.S. COMMERCIALIZATION AGREEMENT WITH CENTAURI HEALTH SOLUTIONS TO ADVANCE AI-DRIVEN ALZHEIMER'S RISK IDENTIFICATION

Alzai Health Corp. has entered into a strategic teaming agreement with Centauri Health Solutions, a leading United States health care technology company serving 60 million members through advanced mission-critical technology, data intelligence and engagement solutions delivered to U.S. health plans, health care providers and health systems.

Under the agreement, Centauri and Alzai will collaborate to market artificial-intelligence-driven risk stratification to identify patients at high risk for early stage undiagnosed Alzheimer's Disease. Centauri will leverage its national relationships with providers and health plans, while Alzai contributes its proprietary AI-driven risk stratification platform and technical expertise. The collaboration accelerates U.S. launch of Alzai's Alzheimer's risk identification technology across Medicare Advantage and other value-based care settings.

"This agreement represents an important milestone in Alzai commercialization and expansion into the U.S. health care market," said Hayim Raclaw, chief executive officer of Alzai Health. "Centauri brings extensive relationships across the health care ecosystem and deep experience supporting health plans and provider organizations. Combining Centauri's market access with Alzai's AI-powered risk identification technology expands our ability to help health care organizations identify individuals at elevated risk for Alzheimer's earlier in the care continuum. Early identification of at-risk individuals has become an increasingly important clinical and economic priority.

"More than seven million Americans are living with Alzheimer's Disease at an estimated cost of $384-billion annually in direct care, according to the Alzheimer's Association. This collaboration aligns with our vision of making pro-active disease identification more accessible and scalable across health care systems. We believe Alzheimer's disease represents one of the most significant unmet needs in healthcare today, and this partnership positions Alzai to participate in one of the most compelling emerging opportunities in preventive health care, population health analytics and AI-driven decision support."

About Alzai Health Corp.

Alzai Health is a health care technology company developing non-invasive, artificial-intelligence-driven disease risk identification solutions using routine health care data. The company's proprietary platform is designed to identify individuals at elevated risk for disease before clinical diagnosis, enabling earlier intervention opportunities and supporting improved patient outcomes. Alzai's technology has been validated on large-scale healthcare data sets and is designed for integration into existing health care infrastructure, including electronic medical record systems, cloud-based environments and enterprise health care platforms.

We seek Safe Harbor.